Meet the podcast team

97. Revisiting the discovery of protein A

What exactly sets protein A apart? Is it really the top choice for antibody purification because of its alphabeticalranking, or is there more to the story? And what about its counterparts, proteins G and L?
View transcript

96. Revisiting protein separation

As we approach our one hundredth episode, travel back with us to the origins of the podcast in our premiereepisode, "Team and Jam and Protein Separation." In this debut, we explored the vital process of proteinseparation—an essential technique in biochemistry and pharmaceuticals that continues to impact human health insignificant ways.
View transcript

95. Convergence of modalities in advanced therapies

Join us as Dr. Aravind Asokan from Duke University explores cutting-edge technologies revolutionizing advancedtherapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges,discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future ofdisease treatment
This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-likeparticles (VLPs).
View transcript

94. Discovery Maker: Dr Michael Houghton

Dive into the fascinating world of virology as we welcome Nobel Prize-winning virologist Dr. Michael Houghton on this episode of Discovery Matters. We explore Dr. Houghton's groundbreaking work in identifying the hepatitis C virus (HCV) and his enduring quest to combat this global health threat.
From the monumental discovery of HCV in 1982 to the revolutionary diagnostic tests that nearly eradicated transfusion-related hepatitis C by the mid-1990s, Dr. Houghton provides an engaging and insightful journey through decades of scientific innovation.
View transcript

93. How sustainable is biopharma?

Eco-design, collaboration, circular economy. These are the bywords of sustainability in biopharma.
Join Ryan Walker, Senior Director of Sustainability at Cytiva, and Aude Arkam, Global Head of Eco-design and Circular Economy at Sanofi, as they explore how these types of initiatives are shaping the future of biopharma.
We delve into challenges, achievements, and the transformational potential of sustainability efforts within biopharma. From Sanofi’s life cycle assessments to industry-wide data difficulties, this episode navigates the complex landscape of creating greener solutions without compromising innovation and compliance.
View transcript

92. Big data, AI, and the problem of averages

In this episode of we dive into the powerful intersection of big data and artificial intelligence. Joined by MatejMacak, a partner from McKinsey, we unravel how AI and machine learning are revolutionizing our approach tofinding new, effective medications.
With Tom Yankeelov, Professor of Biomedical Engineering, Diagnostic Medicine, Oncology at the University of Texasfor Austin, we'll explore the "problem of averages" and much more.
View transcript

91. The body as a bioreactor

What does 'the body as a bioreactor' mean? In this discussion how scientists use the body's machinery to produce therapeutic proteins. Scott Ripley, General Manager of Nucleic Acids at Cytiva, explains that traditional bioprocessing uses external bioreactors, while the new approach leverages the body's natural processes. This method offers benefits like longer protein half-life and the ability to express multiple proteins simultaneously. Justin Eyquem, assistant professor at University of California San Francisco, discusses the potential of in vivo CAR T cell therapy, which could simplify manufacturing and reduce costs. Both approaches face challenges in quality assurance and regulatory approval but hold promise for personalized and more effective treatments.
View transcript

90. What's next for advanced therapies?

Can you tell the difference between a human and AI? Of course you can…right? We challenge Conor and Dodi to tell the difference between Conor and Conor BOT all while uncovering how AI is transforming the life sciences.
We're diving into advanced therapies with industry leaders. Emmanuel Abate, President of Genomic Medicine at Cytiva discussed the strategies to accelerate clinical work and reduce costs. Nathaniel Wang, CEO and Co-Founder of Replicate Bioscience highlighted their groundbreaking self-replicating RNA technology, showcasing impressive clinical results for a rabies vaccine. Both experts emphasized the momentum in biotech, the potential of AI in advancing science, and the importance of making innovative therapies accessible globally. Stay tuned for these insights.
View transcript

89. Unlocking advanced therapies

On Discovery Matters this week, Dodi and Conor are joined by Daria Donati, Chief Scientific Officer of Genomic Medicine at Cytiva, as well as Jen Moody, Vice President of External Innovation of Genomic Medicines at Danaher, to discuss the science, progress, and potential of advanced therapeutics. Demaris Mills, Group Executive of Genomic Medicines at IDT, and experts Fyodor Urnov, Professor of Molecular and Cell Biology at the University of California, Berkeley, and the Director of Technology & Translation at the Innovative Genomics Institute, cover the technologies used in gene and cell therapies as well as CRISPR to deliver powerful and precise treatments aiming for a healthier future.
View transcript

88. Replicants and reality

Uncover how AI is transforming the life sciences. Together with an AI-bot, known as Conor BOT, the pair explore the potential applications of AI in drug discovery, personalizing medical treatments, protein folding, and more. They also consider the ethical considerations required when developing AI models, as well as the need for emotional intelligence in AI systems. Don't miss this fascinating exploration and discussion of the changing landscape of the life sciences! Tune in to this episode of Discovery Matters to learn more about AI and its role in the life sciences.
View transcript

87. Cephalopods: From camouflage to communication

Joined by Dan Wilson from the Costas Research Institute at Northeastern University, we dive into the fascinating research behind the development of paints that respond to environmental stimuli, such as sunlight. They also discuss titanium dioxide and how it acts as a facilitator of the color-changing process. Professor Alon Gorodetsky, Associate Professor of Chemical and Biomolecular Engineering at the University of California, Irvine, talks about his research on developing energy-responsive dyes to mimic the features of octopi. Discover the potential applications of these dyes from diagnostics to resource-constrained initiatives, and more.
View transcript

86. Synthetic biology

In this episode of Discovery Matters, hosts Dodi and Conor explore how synthetic biology can lead to transformative breakthroughs when it comes to dealing with global health problems. Through their conversation with Justin Vigar, a PhD student in Dr. Keith Pardee's lab at the University of Toronto in Canada, we learn how his paper-based diagnostic tool has the potential to provide faster, more cost-efficient, and accessible diagnostics for underserved locations. This is complemented by Amir Pandi and Tobi Erb's discussion of using AI and synthetic biology to develop new antimicrobial peptides.
View transcript

85. How can we drug the undruggable?

Tune in to Discovery Matters to see how we can drug the undruggable. Dodi and Conor talk to Mark Bray, a second year PhD student in the Bowman Lab at the University of Pennsylvania, about the concept of “drugging the undruggable” for drug discovery and development. They discuss advances in medical research which has enabled us to drug molecular targets that were previously inaccessible, and the strategies that are used to devise and find effective drugs. Vicky Richon, CEO at Entact Bio, elucidates the importance of a revolutionary “induced proximity” modality for unprecedented drug treatments. Listen to this episode to understand modern approaches to treating diseases and uncovering cures.
View transcript

84. Unraveling biotech's AI transformation

Explore the potential of artificial intelligence (AI) and machine learning to revolutionize biomedical research and make personalized healthcare a reality.

Tune in to Discovery Matters to see how AI and machine learning will be the future of biomedical research. Featuring interviews with Professor Kourosh Saeb-Parsy and Dr Namshik Han — leaders in the AI and biotech space — this episode delves into the significance of advanced technology for unlocking discoveries in transplantation, understanding the causes of diseases, precision medicine, and more.
View transcript

83. Antibody drug conjugates

Let’s explore the world of antibody drug conjugates (ADCs) and their potential for improving human health. Our two guests—Principal Investigator Sasha Ebrahimi from GSK and oncologist Dr. Paolo Tarantino—discuss the development and advantages of ADCs, and how they can be used to personalize treatments for cancer and other illnesses. Sasha explains how ADCs combine the targeting capabilities of antibodies with the cytotoxic effects of drugs, while Dr. Tarantino delves into his own research with breast cancer and immunotherapies. Learn more about the possibilities of ADCs in this insightful episode of Discovery Matters.
View transcript

82. Best of 2023

Are cells really conscious and can marine microbes fight cancer? On the Discovery Matters, we look back on potential therapies that could revolutionize healthcare. From exploring revitalized therapies such as psychedelics, to delving into patient-derived organoids and freeze-preserved stem cells, to studying the formation of earth-like planets found in the harshest of environments, we dive into some of the most important and exciting research breakthroughs of the year. Join Dodi and Conor in this episode to learn more about the possibilities of science and the implications for healthcare and patient care. Tune in and never underestimate the power of discovery!
View transcript

81. Access in developing nations

Challenges of improving access to healthcare in developing countries - it's a conversation we need to have. With the help of Dr Jerome Kim, Director General of the International Vaccine Institute, we discuss vaccination and immunization programs as a key aspect of public health and global development – especially in developing nations, where access to life-saving medicines is often limited or non-existent. Karen Heichman, Deputy Director of Diagnostics, Bill and Melinda Gates Foundation, takes us on a journey on the critical role of diagnostics in the fight against diseases.
View transcript

80. Different strokes from different folks

Join Conor and Dodi in the latest episode of Discovery Matters, as they explore the wonders of ground-breaking scientific discoveries from multidisciplinary collaboration. MIT's Professor Pete Dedon expresses how multidisciplinary approaches and unique combinations of experiences can help to produce unexpected results. Professor James Evans of the University of Chicago then brings in the concept of surprise and hypergraphs to uncover the connections between different fields of knowledge. With insights from their guests, the latest episode of Discovery Matters dives deep into the mechanics behind groundbreaking discoveries. Jump in and listen to discover new ways to think about innovations and uncover the next amazing breakthrough!
View transcript

79. Patient-derived organoids (part 2): Organic electronic materials

Let’s explore the world of organoids and their potential to revolutionize the way we treat diseases. Joined by Matthias Zilbauer and Roisin Owens, we look at the interplay of the gut-brain axis with the use of organic electronic materials. Dive into the advances in organoid and microbial models used to develop treatments for illnesses such as Irritable Bowel Syndrome (IBS), Crohn’s Disease, and Ulcerative Colitis. Join Dodi and Conor to find out how bioengineering could change our understanding of health and disease - and our own lives.
View transcript

78. Lipid nanoparticles: a special delivery service

In this episode of Discovery Matters, we sit down with Dan Peer to discuss the exciting potential of lipid nanoparticles (LNPs) to deliver genetic material and therapeutics to target cells and tissues, with the goal of improving human health. Dan shares how his team has developed siRNA LNPs to deliver treatment more efficiently for ovarian cancer patients. He describes the promise of mRNA therapies and delivery systems to reduce side-effects and improve patient outcomes. From Dan's unique perspective, learn why this technology is cutting edge, and why it may help defeat one of mankind’s biggest enemies— cancer. Tune in to this episode and learn more about Dan's work and the unique potential of LNPs.
View transcript

77. Combination therapies and serendipity

This episode is all about combination therapies. We dive into the mysterious power of the human microbiome and its importance in modern health, as well as the power of serendipity in understanding and treating anti-microbial resistance

Through a discussion of combination therapies, Dodi and Conor delve into the mysterious power of the human microbiome, and antimicrobial resistance. With evidence of the microbiome playing a key role in fighting diseases, this episode highlights the importance of understanding the microbiome and its potential to improve lives. Tune in to find out more and explore the possibilities of the microbiome with Dr Saman Maleki, and the power of serendipity with Prof Pete Dedon!
View transcript

76. Liquid biopsy

In this episode, we dive into the potential of liquid biopsies as a method to detect deadly diseases. We speak with three experts – Marta Herreros, Rik Bryan, and Doug Ward – to learn more about the non-invasive nature of liquid biopsies and the process of detecting biomarkers within a patient sample. Rik and Doug discuss their GALEAS Bladder test, which can identify key mutations present in 96% of bladder cancer patients. Tune in to learn more about the potential of liquid biopsies and the importance of early detection!
View transcript

75. The state of the industry

Why do China and US have different government regulations? Why can’t we do business above the fray?

These are just some of the struggles biopharma executives report as impacting their business. Our guests are of the same view – the industry needs fixing.

Yingke He, CEO and Co-Founder of Forecyte Bio, explains how China's industrialized experience is limited and in its early stages compared to the US.

Listen to this episode to understand the industry tensions and areas showing promise.
View transcript

74. Patient-derived organoids

In this episode of Discovery Matters, we explore the incredible advances in precision medicine enabled by organoid technology. Vicky Marsh Durban and Oksana Sirenko contribute to the conversation, talking about how machine learning and robotics are used to scale up organoid culture and analyse data, as well as the potential of organoids to revolutionise regenerative medicine. Listen in to this episode for an insightful and informative deep dive into the potential of organoids for transforming the face of modern medicine.
View transcript

73. War! What is it good for?

War! What is it good for? In this episode of Discovery Matters, Dr. Smith explains how military medicine first shaped state medicine and how wartime creates an opportunity to innovate. From advances in prosthetics, psychology, and cosmetic surgery to the mass production of penicillin during World War II, this episode dives deep into the life-saving innovations brought over the line due to conflicts.
View transcript

72. Pioneers and visionaries – Cryogenic cold chains

On the latest episode of Discovery Matters, Dodi and Conor are joined by John Morris, a scientist at the forefront of cryopreservation technology. They discuss cryopreservation's impact on CAR-T therapies' development, why freezing cells is essential to these treatments, how tracking the samples ensures quality and the potential for frozen cells to treat solid tumors in the future. Tune in to find out how cryopreservation has transformed the life sciences and how it could revolutionize how we treat disease in the future.
View transcript

71. Revived therapies (part 2) – Phage therapy

Conor and Dodi explore the new and exciting world of bacteriophage therapy. Join them as they speak to Anton Peleg, Professor of Infectious Diseases and Microbiology, and the Director of the Department of Infectious Diseases at the Alfred Hospital and Monash University, about this emerging field. Together they discuss how phages, viruses that specifically target bacteria, are being used to fight against antibiotic-resistant superbugs the challenges of producing them at scale and getting them approved by regulatory bodies.

Tune in to Discovery Matters to learn all this and more and join the conversation about these important advances in life sciences.
View transcript

70. Anti-cancer molecule

In the latest episode of Discovery Matters, Dodi and Conor are joined by Dr. Bradley Moore from the Scripps Institution of Oceanography to discuss his research into the medical and synthetic implications of using marine microbes to fight aggressive cancers such as glioblastoma. By leveraging salinosporamide A, Dr. Moore proposes that these deep-sea organisms could potentially be scaled up for human use and repurposed for medicinal and synthetic purposes. Dive into this episode to hear how the ocean has the power to bring forth new discoveries that could save lives!
View transcript

69. Never underestimate a cell

We should not underestimate cells. Conor and Dodi talk with Dr Brett Kagan who conducted research to understand the brain and test ‘sentient’ brain cells, using the 1970s game, known as ‘Pong’. In another conversation, Professor Petra Levin and Kunaal Joshi explain how they have demonstrated that there is no ‘average’ life of a cell.

At the end of this episode, we hope to have proven that cells are not to be overlooked and still have so much to tell us about human health.
View transcript

68. CRISPR and molecular aging

What do CRISPR and longevity have in common? Not much, except it's all molecular.

We speak to two different CEOs focused on improving human health. We begin with Dr Benjamin Oakes, Co-Founder, President, and CEO of Scribe Therapeutics who takes us through the discovery, potential, and possible limitations of CRISPR.

Then we are joined by fellow visionary, Dr Kristen Fortney, the CEO, and co-founder of BioAge, a clinical stage biotechnology company developing therapies that treat disease by targeting the biology of ageing.
View transcript

67. Revived therapies (part 1) – Psychedelics

Psychedelic treatment is a therapy which is on the rise according to the increasing number of studies on the use of psylocibin, ketamine and MDMA to treat mental health disorders such as PTSD. In this episode, Conor talks to Prof. Eric Vermetten, a psychiatrist who has been working with the military in the Netherlands for the last 25 years helping Dutch armed forces and the uniformed people in the face of PTSD and psychotraumatology.
View transcript

66. Getting ÄKTA ready in virtual reality

Conor and Dodi try their hand at learning to operate an ÄKTA ready in virtual reality. Their virtual journey takes them to Singapore and Miami, without leaving Sweden, Amersham, and Edinburgh. Join us on a journey into the metaverse.
View transcript

65. Best of 2022

Mushrooms on Mars, life-saving blood from worms, cell-cultured seafood. It's been a year filled with surprise, serendipity, and everything in between. Conor, Dodi, and the podcast team look back on a fascinating year and highlight their favorite interviews and topics of the year.
View transcript

64. Pain in the body and the brain

In this episode, we are focusing intently on the microbiome and how it is increasingly being linked to disease and illness. It seems that this is true for understanding illness of the body and the brain. Dr Amir Minerbi, the Deputy Director of the Institute for Pain Medicine at Rambam Medical Center in Haifa, Israel talks to us about how the microbiome may hold the secrets of fibromyalgia. This chronic disorder causes widespread pain, fatigue, cognitive dysfunction, and potentially dozens of other symptoms.
We are also joined by Prof Illana Gozes, Director of Elton Laboratory for Molecular Neuroendocrinology in the Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine in Tel Aviv University. She elaborates on her research surrounding the role of specific microbiota signatures as a biomarker for PTSD.
The link between physical and mental health and the microbiome is a fascinating connection, and one we intend to explore to the fullest.
View transcript

63. Organ on a chip: Part 2

In this second episode of a two-part series on organ on a chip technology, we sit down with Christos Michas, R&D scientist and engineer at Curi Bio, and Alice White, professor of mechanical engineering at Boston University. Christos and Alice are taking the organ on a chip to another level with the miniPUMP, a heart on a chip which is the first step in understanding the interaction of therapeutic drugs on the heart. As cardiovascular diseases are one of the leading causes of death in the industrialized world, there is a lot of interest in understanding how these diseases emerge and how we can develop therapeutics.
View transcript

62. Organ on a chip: Part 1

In this first episode of a two-part series on organ on a chip technology, we discuss with Jan Turner, formerly part of Safer Medicines Trust, how these organoids can help us move away from the inefficient animal model.
View transcript

61. Genetic and genomic databases

We have a lot of information at our fingertips, so how do we make sense of it all to transform human health? Conor and Dodi speak to two experts who are making sense of this information overload by creating genetic and genomic databases. Dr Artem Babaian, a computational biologist and now Assistant Professor leading The Laboratory for RNA-Based Lifeforms at the University of Toronto, explains how he and his team uncovered 100 000 novel viruses in old genetic data that could help us predict future pandemics. Professor Jinchuan Xing, Associate Professor at Rutgers University in the Department of Genetics doing research on genomic variation, walks us through his study on using genomic data to predict infertility from aneuploid egg production.
View transcript

60. The talk on talent

Within the life sciences industry, there has been a longstanding conversation around one of the industry’s most difficult challenges. That challenge is talent. In more detail, it is that the access to a global talent pool remains difficult. In this longer than usual conversation, Conor and Dodi speak with Darrin Morrissey, the CEO of NIBRT, Anne-Cecile Potmans, general manager of Fast Trak and CDMO services at Cytiva, and Nikki Soares, global talent acquisition leader at Cytiva.
View transcript

59. Microscopic eco-warriors

Plastic and pollution are two issues that impact our planet. It would be easy to despair but once again biology has come to save us. The Alper Lab at University of Texas at Austin has engineered a plastic-eating enzyme which can shorten plastic degradation from hundreds of years to 48 hours. We speak to Dr Hal Alper, Professor in Chemical Engineering at UT at Austin, who engineered this heroic enzyme. We also speak to Marco Poletto, director and co-founder of EcoLogic studio, which is a design innovation company specializing in biotechnology for the built environment. He explains his use of microalgae to create streetlights, playgrounds, and biofilms on the outside of buildings which can capture 20 large trees worth of CO2 every day.
View transcript

58. Wastewater epidemiology: Something in the wastewater

We speak to Prof. Dominic Frigon, a specialist of biological wastewater resource recovery at McGill University, who used this technique in Quebec through the pandemic to determine areas of vulnerability, including a homeless shelter. We also speak to Dr Kata Farkas, an environmental virologist at Bangor University, to understand the wider applications and importance of this analysis technique.
View transcript

57. Special blood and transplants

This episode is all about special blood and transplants. We speak to Jon Adkins, co-founder of XenoTherapeutics, who walks us through their use of xenotransplantation for skin grafts and organ transplantation. We are also joined by Dr. Franck Zal, a marine biologist, CSO and CEO of Hemarina, to discuss the lugworm. His discovery, that the lugworms’ blood is compatible with human blood, means it can be used in medical applications for transplants.
View transcript

56. Understanding and treating Alzheimer’s

In this episode, we contemplate combatting the devastating disease that is Alzheimer’s. We talk to two experts leading two respective early-stage studies into possible treatments for Alzheimer’s. On the one hand, Dr Joshua Hare, co-founder of Longeveron, is looking at treating aging rather than the disease itself. On the other hand, Dr Lucy Vivash, a research fellow at Monash University, looks at the tackling of tau proteins.
View transcript

55. Injustice of disease burden and access to vaccines

The pandemic has been a global issue, which has benefitted from the coming together of industry, pharma, academia, non-governmental and governmental support. What it has also brought into sharp focus is the global imbalance access to healthcare and health inequity between the Global North and Global South.
View transcript

54. Mycoprotein v. cell-cultured seafood

We discuss the environmentally friendly alternative foods to meat consumption. We take a deep dive into mycoprotein and cell-cultured seafood.
View transcript

53. The future of GMOs

The future of food: GMOs. In this episode, we discuss cell cultured chocolate, and growing and consuming plants in space
View transcript

52. The magical world of fungi (part 2)

Fungi are amazing in so many ways. Did you know that fungi can be used for building materials in low resource environments? Or that they could decrease the carbon in our atmosphere? Or that they could bring extra income for low-resource communities? Chris explains that he has been using mushrooms to make building materials in low-resource environments in Namibia. These materials prove even better than concrete.
View transcript